Pancreaticoduodenectomy for duodenal papilla carcinoma: A single-centre 9-year retrospective study of 112 patients with long-term follow-up

Table 1 The serum levels of CA19-9 and CEA and clinical characteristics for 112 patients with duodenal papilla carcinoma

Characteristic	No.	Serum CA19-9		P value	Serum CEA		P value
		Negative	Positive		Negative	Positive
Gender				0.350			0.807
Male	74	46	28		63	11
Female	38	27	11		33	5
Age (yr)				0.621			0.699
< 60	61	41	20		53	8
> 60	51	32	19		43	8
Duration (yr)				0.938			0.699
< 1	54	35	19		47	7
> 1	58	38	20		49	9
Serum CA19-9 (U/mL)							0.000
< 120	73				69	4
> 120	39				27	12
Serum CEA (ng/mL)				0.000
< 5	96	69	27
> 5	16	4	12
Serum total bilirubin (μmol/L)				0.105			0.526
< 34.2	43	32	11		38	5
> 34.2	69	41	28		58	11
Bile pre-drainage				0.945			0.933
No	78	51	27		67	11
Yes	34	22	12		29	5
Tumour diameter (cm)				0.820			0.934
< 2	76	49	27		65	11
> 2	36	24	12		31	5
Pancreatic duct diameter (mm)				0.351			0.015
< 4	78	53	25		71	7
> 4	34	20	14		25	9
Drainage mode				0.033			0.928
Inside	85	60	25		73	12
Outside	27	13	14		23	4
End-to-end invagination				0.184			0.145
No	90	56	34		75	15
Yes	22	17	5		21	1
Blood loss (mL)				0.786			0.059
< 400	67	43	24		54	13
> 400	45	30	15		42	3
Delayed emptying				0.227			0.350
No	107	71	36		91	16
Yes	5	2	3		5	0
Pancreatic fistula				0.874			0.166
No	91	59	32		76	15
Yes	21	14	7		20	1
Differentiation				0.253			0.033
Well	40	24	16		37	3
Moderate	38	23	15		28	10
Poor	34	26	8		31	3
T stage				0.946			0.062
T1	14	10	4		14	0
T2	34	22	12		31	3
T3	35	23	12		30	5
T4	29	18	11		21	8
N stage				0.078			0.301
N0	88	61	27		77	11
N1	24	12	12		19	5
TNM stage				0.682			0.109
IA	14	10	4		14	0
IB	27	18	9		25	2
IIA	28	20	8		24	4
IIB	14	7	7		12	2
III